Global Veletri Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Veletri market size was valued at US$ 115 million in 2025 and is forecast to a readjusted size of US$ 164 million by 2032 with a CAGR of 5.2% during review period.
Veletri (Epoprostenol) is a synthetic prostacyclin (PGI₂) derivative developed by Actelion (now part of Johnson & Johnson) and is the first approved continuous intravenous formulation for the treatment of Pulmonary Arterial Hypertension (PAH). It acts by activating PGI₂ receptors, leading to vascular smooth muscle relaxation, pulmonary vasodilation, and inhibition of platelet aggregation, thereby reducing pulmonary vascular resistance and improving right ventricular function. Compared with the earlier formulation Flolan, Veletri features an enhanced formulation that remains stable at room temperature, simplifying preparation and infusion processes while improving patient adherence and clinical efficiency. Veletri is widely used for long-term management of moderate to severe PAH and is recognized globally as the benchmark therapy among intravenous prostacyclin drugs.In 2024, global Veletri production reached approximately 1.76 m units, with an average global market price of around US$ 60 perunit.The average gross profit margin of this product is 75%.
The global management of pulmonary arterial hypertension (PAH) is shifting from single-drug therapy toward multi-target combination, long-term management, and personalized precision treatment. As the first room-temperature-stable intravenous prostacyclin formulation, Veletri offers improved safety, operability, and adherence, positioning it as a key component of standard clinical regimens. Government initiatives supporting rare disease and high-value drug access, coupled with expanded reimbursement frameworks, enhance Veletri’s accessibility. Meanwhile, major pharmaceutical companies are investing heavily in cardiopulmonary rare disease innovation, driving the commercial potential of Epoprostenol in combination therapies and integrated drug-device solutions.
Veletri continues to face structural challenges such as high treatment cost, infusion dependency, and operational complexity. Its requirement for continuous intravenous administration and strict aseptic handling places demands on clinical training and patient compliance. The market is becoming more competitive with the rise of next-generation prostacyclin analogs such as Treprostinil, Iloprost, and Selexipag. Increasing payer pressure in emerging markets constrains adoption, while stringent quality requirements for raw materials and solvent systems make supply chain reliability a critical factor influencing growth.
Clinical demand is expanding from late-stage PAH patients to earlier disease management. Physicians increasingly favor combination regimens integrating prostacyclin-pathway drugs with endothelin receptor antagonists and PDE5 inhibitors. Veletri remains the “gold standard” for intravenous therapy due to its proven efficacy and trusted brand image. Specialized cardiopulmonary centers are adopting remote infusion monitoring, smart pump systems, and digital therapy platforms to support home-based care. Research institutions are also exploring new indications such as acute pulmonary hypertensive crises and right heart failure, extending Veletri’s therapeutic reach.
The key materials for Veletri include high-purity Epoprostenol Sodium, stabilized solvent systems (based on glycerol, carbamate, and buffer solutions), and medical-grade infusion components. Production is highly sensitive to temperature, humidity, and oxidation, requiring synthesis and packaging under strict anhydrous, anaerobic conditions. Upstream supply primarily comes from GMP-certified manufacturers in Europe and Japan, with partial localization of excipients. Advances in intermediate synthesis and lyophilization technology have significantly enhanced room-temperature stability and logistics reliability, strengthening the global supply framework for Veletri.
This report is a detailed and comprehensive analysis for global Veletri market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Veletri market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Veletri market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Veletri market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Veletri market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Veletri
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Veletri market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, GlaxoSmithKline, Sun Pharmaceutical, Teva, Viatris, Fuji Seiyaku Kogyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Veletri market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Intravenous Formulation
Inhalation Formulation
Market segment by Clinical Indications
Pulmonary Arterial Hypertension
Control of Postoperative Acute Pulmonary Hypertension
Market segment by Sales Channel
Online
Offline
Market segment by Application
Hospitals
Home Infusion Therapy
Major players covered
Johnson & Johnson
GlaxoSmithKline
Sun Pharmaceutical
Teva
Viatris
Fuji Seiyaku Kogyo
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Veletri product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Veletri, with price, sales quantity, revenue, and global market share of Veletri from 2021 to 2026.
Chapter 3, the Veletri competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Veletri breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Veletri market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Veletri.
Chapter 14 and 15, to describe Veletri sales channel, distributors, customers, research findings and conclusion.